WO1981002975A1 - Formulation d'un medicament a action prolongee - Google Patents

Formulation d'un medicament a action prolongee Download PDF

Info

Publication number
WO1981002975A1
WO1981002975A1 PCT/US1981/000520 US8100520W WO8102975A1 WO 1981002975 A1 WO1981002975 A1 WO 1981002975A1 US 8100520 W US8100520 W US 8100520W WO 8102975 A1 WO8102975 A1 WO 8102975A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
derivative
combination
formulation
improvement
Prior art date
Application number
PCT/US1981/000520
Other languages
English (en)
Inventor
J Swarbrick
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Priority to AU72201/81A priority Critical patent/AU7220181A/en
Publication of WO1981002975A1 publication Critical patent/WO1981002975A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems

Definitions

  • drugs have been encapsulated in polymer or in slowly- dissolving coating material, or have been dispersed in an insoluble or slowly-dissolving matrix.
  • Prolonged activity formulations designed for subcutaneous and intramuscular injection have been prepared by using polymers to complex
  • the present invention provides a prolonged ac ⁇ tion drug formulation in which a chemical derivative of the desired drug is utilized.
  • concentration of the drug derivative is such as to provide only minor pharmacological activity.
  • the derivative retains its identity, but in combination with desired quantities of the drug itself, serving by such combination to impede the release of the drug.
  • the desired drug is dispersed in a suitable chemical derivative which has a reduced aqueous solubility and reduced dissolution rate.
  • the pharmacological activity of the modified drug is minor relative to the activity of the drug with which it is in combination, there is little likelihood of pharmacological and biochemical changes in the derivative; there is thus a cost savings through reduced toxicity testing and dosage development time.
  • the relationship between drug release and concentration in the combination can be readily deter ⁇ mined and customized for any particular application by simple changes in concentration and/or the manner by which the drug and derivative are placed in combination.
  • the derivative will eventually break down and be removed undergoing a reaction such as hydrolysis to reform the original drug.
  • the prolonged action drug formulation of the present invention comprises, in combi ⁇ nation, a pharmacologically effective amount of a drug in solid form and a solid chemical derivative of the drug in a concentration which is sufficient to substantially pro ⁇ long the time during which the drug is pharmacologically active but having at that concentration only minor pharma cological activity relative to the drug.
  • the combination is preferably a substantially intimate and uniform mixtur for example obtained by physical admixture fallowed by compaction and comminution, or by coprecipitation from a common solution, or the drug and derivative can be melted together to form a fused solid; alternatively, the deriva tive can be coated onto, or otherwise encapsulate, par- tides of the drug.
  • the combination has particular use ⁇ fulness when administered subcutaneously or intramuscu ⁇ larly.
  • the aqueous solubility (in pH 7 phosphate buffered solution) of the derivative should be less than 0.20 mg./ml., preferably less than 0.01 mg./ml.
  • the drug will generally constitute about. 25-95 weight percent of the combination.
  • a pharmacologically appropriate derivative of the following drugs that are amenable to chemical modification: steroids, neuroleptics , beta-lactam antibiotics, antileprotics, antimalarials , hypoglycemics, narcotics and narcotic antagonists.
  • the main invention is exemplified with reference to the antileprotic drug diaminodiphenyl sulfone, commonly known as dapsone. This is the drug of choice in the treat ⁇ ment of leprosy, having strong pharmacological activity against the bacillus Mycobacterium leprae. Typical dosage is 50-100 milligrams per day for a period of five years or longer.
  • acedapsone is reported by Sinkula as having an aqueous solubility (pH 7 phosphate buffered solution) of 0.003 mg./ml.
  • acedapsone When used as a "prodrug", i.e., a compound which is biotransformed into its pharmacologically active form, sufficient amount of the derivative must be used to provide the required dosage amount of the parent drug.
  • the acedapsone serves not as the source of the dapsone but physically as a matrix or coating to con ⁇ trol the release of the dapsone with which it is present in combination.
  • the required amount of acedapsone is much lower than when it is used as a prodrug.
  • O PI acedapsone has only minor pharmacological activity rela ⁇ tive to the dapsone component.
  • steroid drug testosterone can be combined with the derivative testos ⁇ terone cypionate
  • the neuroleptic drug fluphenazine can be combined with the derivative fluphenazine decanoate
  • the beta-lactam antiobiotic drug benzylpenicillin can be combined with the derivative benzathine penicillin G
  • the antimalarial drug cycloguanil can be combined with the derivative cycloguanil pamoate
  • the hypoglycemic drug insulin can be combined with the alkanedioic acid deriva ⁇ tive of insulin
  • the analgesic propoxythene can be com ⁇ bined with the derivative propoxythene napsylate
  • the narcotic antagonist naloxone can be combined with the derivative naloxone napsylate.
  • the components should preferably be intimately and uniformly dispersed which can be accomplished by compaction of a simple admixture and comminution.
  • a simple admixture and comminution As an alternative to physical admixture, one can obtain a sub ⁇ stantially intimate and uniform combination by coprecipi- tation of the drug with the derivative.
  • the coprecipitate is prepared by either removing the solvent in vacuo or adding a liquid iscible with the solvent but in which both drug and the derivative have only a low solubility.
  • Another method of combining the components is to melt the combination to form a fused solid upon cooling,
  • the combination can be used in accordance with any procedure in which the drug or prodrug has been used.
  • it can be suspended in aqueous solution or in oil, as appropriate, and injected as a suspension.
  • the material can be implanted in the form of a pellet or as a thin wafer, or injected as microcap- sules. Because a substantially smaller amount of the derivative is used in the present context than as a pro- drug, one can stay within reasonable bounds of injection volume, for example 2 ml or less for subcutaneous injec ⁇ tion and 5 ml or less for intramuscular injection.
  • Example II The procedure of Example I is repeated except that the combination is obtained by coprecipitation of the dapsone and acedapsone from common solution. In this regard, one can dissolve both dapsone and acedapsone in the minimum amount of the solvent dimethylformamide. A coprecipitate is formed on the addition of an excess of water, separated by filtration and subsequently dried. The resultant combination is treated as in Example I.
  • a combination is obtained by physically admixin in a mortar and pestle 0.5 grams of dapsone and 0.5 grams of acedapsone. The combination is compressed in a suitab punch and die assembly to -a pellet weighing 1.0 grams eac The pellets are then implanted subcutaneously, the wound being sutured for complete enclosure of the implant. Because of the biodegradable nature of the component, no subsequent recovery of the implant is required.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Le temps pendant lequel un medicament est pharmacologiquement actif est prolonge en combinant le medicament avec un derive chimique du medicament ayant une faible activite pharmacologique par rapport au medicament.
PCT/US1981/000520 1980-04-21 1981-04-20 Formulation d'un medicament a action prolongee WO1981002975A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU72201/81A AU7220181A (en) 1980-04-21 1981-04-20 Prolonged action drug formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14227980A 1980-04-21 1980-04-21
US142279 1980-04-21

Publications (1)

Publication Number Publication Date
WO1981002975A1 true WO1981002975A1 (fr) 1981-10-29

Family

ID=22499269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1981/000520 WO1981002975A1 (fr) 1980-04-21 1981-04-20 Formulation d'un medicament a action prolongee

Country Status (2)

Country Link
EP (1) EP0050650A1 (fr)
WO (1) WO1981002975A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000852A1 (fr) * 1987-07-29 1989-02-09 The Upjohn Company Liberation commandee de sels antibiotiques a partir d'un implant
GB2380147A (en) * 2000-11-09 2003-04-02 Bradford Particle Design Ltd Particulate products
US9616060B2 (en) 2002-04-17 2017-04-11 Nektar Therapeutics Particulate materials
US9700529B2 (en) 2002-05-03 2017-07-11 Nektar Therapeutics Particulate materials
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
US9833451B2 (en) 2007-02-11 2017-12-05 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Drugs and Pharm. Sciences, Chapter 6, Vol. 6 (1978) pp. 411-548 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000852A1 (fr) * 1987-07-29 1989-02-09 The Upjohn Company Liberation commandee de sels antibiotiques a partir d'un implant
GB2380147A (en) * 2000-11-09 2003-04-02 Bradford Particle Design Ltd Particulate products
US7115280B2 (en) 2000-11-09 2006-10-03 Nektar Therapeutics Uk, Ltd. Particle formation methods and their products
US9120031B2 (en) 2000-11-09 2015-09-01 Nektar Therapeutics Compositions of particulate coformulation
US10798955B2 (en) 2000-11-09 2020-10-13 Nektar Therapeutics Compositions of particulate coformulation
US9616060B2 (en) 2002-04-17 2017-04-11 Nektar Therapeutics Particulate materials
US10251881B2 (en) 2002-04-17 2019-04-09 Nektar Therapeutics Particulate materials
US10188614B2 (en) 2002-05-03 2019-01-29 Nektar Therapeutics Particulate materials
US9700529B2 (en) 2002-05-03 2017-07-11 Nektar Therapeutics Particulate materials
US10945972B2 (en) 2002-05-03 2021-03-16 Nektar Therapeutics Particulate materials
US10172853B2 (en) 2007-02-11 2019-01-08 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US9833451B2 (en) 2007-02-11 2017-12-05 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition

Also Published As

Publication number Publication date
EP0050650A1 (fr) 1982-05-05

Similar Documents

Publication Publication Date Title
KR100730440B1 (ko) 주사가능한 부프레노르핀 미세 입자 조성물 및 이의 용도
AU705737B2 (en) Prolonged nerve blockage by the combination of local anesthetics and glucocorticoids
EP0290891B1 (fr) Système à libération retardée d'un médicament pour le traitement des troubles nerveux
Maulding Prolonged delivery of peptides by microcapsules
US20210212934A1 (en) Methods for providing long-lasting anesthetic effect using microparticles
NO975708L (no) Blanding for vedvarende frigjöring av humant veksthormon
JP2001515862A (ja) 制御放出微小球体デリバリーシステム
EP0659073A1 (fr) Matrices en polymere biodegradables pour la liberation prolongee d'agents anesthesiants locaux
CA2265561A1 (fr) Formulations et methodes pour assurer une anesthesie locale prolongee
KR102507678B1 (ko) 아리피프라졸 서방형 미소구체 및 이의 제조 방법
WO2006032202A1 (fr) Formulation à libération lente et prolongée contenant un agoniste du récepteur de la dopamine et son procédé de préparation
US20050048115A1 (en) Buprenorphine microspheres
CA2064861A1 (fr) Galenique injectable a effet retarde
JPH10511365A (ja) 遅延性ｇｌｐ−１組成物
US5858393A (en) Transdermal formulation
WO1981002975A1 (fr) Formulation d'un medicament a action prolongee
CN101380291A (zh) 一种缓释注射剂及其制备方法
CN101380292A (zh) 一种缓释注射剂及其制备方法和应用
CA1168581A (fr) Formulation de medicaments a action prolongee
US4731359A (en) Prolonged action drug formulation
US4461776A (en) Prolonged action drug formulation
Uebel et al. Stability evaluation of a prostaglandin E1 saline solution packed in insulin syringes
Lim Development of Local Drug Delivery System: Prolonged Sciatic Nerve Blockade From Biodegradable Microspheres
Lin Buprenorphine microspheres: Formulations, dissolution, and subcutaneous absorption
GR1009871B (el) Φαρμακευτικο σκευασμα που περιλαμβανει μικροσφαιριδια ναλτρεξονης και μεθοδος παρασκευης αυτου

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU DK JP

AL Designated countries for regional patents

Designated state(s): CH DE FR GB NL SE